Objective: To study the efficacy of topical epigallocatechin gallate (EGCG) for the treatment of dry eye disease (DED).
in the controlled environment chamber to induce DED. Topical 0.01% or 0.1% EGCG, or vehicle, was applied to the eyes of DED mice. Corneal fluorescein staining and the number of corneal CD11b+ cells were assessed in the different groups. Expression of interleukin-1b, tumor necrosis factor-a, chemokine ligand 2, and vascular endothelial growth factor (VEGF)-A/C/D was evaluated by real-time polymerase chain reaction in the corneas at day 9. Corneas were stained for lymphatic vessel endothelial hyaluronan receptor (LYVE)-1 to evaluate lymphangiogenesis, and the terminal transferase dUTP nick end labeling (TUNEL) assay was used to evaluate apoptosis of corneal epithelial cells.
Results: Treatment with 0.1% EGCG showed a significant decrease in corneal fluorescein staining compared with the vehicle (24.6%, P = 0.001) and untreated controls (41.9%, P , 0.001). A significant decrease in the number of CD11b+ cells was observed in 0.1% EGCG-treated eyes, compared with the vehicle in the peripheral (23.3%, P = 0.001) and central (26.1%, P = 0.009) corneas. Treatment with 0.1% EGCG was associated with a significant decrease in the corneal expression of interleukin-1b (P = 0.029) and chemokine ligand 2 (P = 0.001) compared with the vehicle and in VEGF-A and VEGF-D levels compared with the untreated group (P = 0.007 and P = 0.048, respectively). EGCG 0.01% also showed a decrease in inflammation at the molecular level but no significant changes in the clinical signs of DED. No cellular toxicity to the corneal epithelium was observed with 0.01% or 0.1% EGCG.
Conclusions: Topical EGCG treatment is able to reduce the clinical signs and inflammatory changes in DED by suppressing the inflammatory cytokine expression and infiltration of CD11b+ cells in the cornea. 1,2 Recently, it has become widely recognized that DED is associated with inflammation of the ocular surface, although its precise immunopathogenesis is still not well understood. [2] [3] [4] [5] Recent studies show evidence for the overexpression of proinflammatory cytokines in the ocular surface of patients and animals with DED.
3,5-9 Several inflammatory mediators, such as interleukin (IL)-1b, IL-6, IL-17, interferon-g, tumor necrosis factor (TNF)-a, chemokine (C-C motif) ligand 2 (CCL2), and a number of matrix metalloproteinases, have been implicated in the ocular surface inflammation associated with DED. 3, [5] [6] [7] [8] In addition, the overexpression of chemokines, such as CCL2, CCL5, and chemokine (C-X-C motif) ligands 9 to 11, could mediate leukocyte and autoreactive T-cell recruitment to the ocular surface in DED. DED induces the generation of autoimmune T cells, predominantly Th17 in the draining lymphoid tissues, which antagonize the regulatory T cell and also peripheralize to the ocular surface and cause epithelial damage. 3, 4, 9 Several investigations have demonstrated that epigallocatechin gallate (EGCG), 1 of the principal extracts of green tea, has an inhibitory effect on the inflammation related to autoimmune disorders. [10] [11] [12] In addition, some studies have demonstrated that green tea extract reduces the expression of IL-1, IL-6, and TNF-a through inhibition of nuclear factor-kB activation and have suggested that green tea may be useful to prevent or ameliorate diseases associated with inflammatory cytokine overexpression. [13] [14] [15] [16] In this study, we hypothesized that topical EGCG administration may have a therapeutic effect for the treatment of dry eyes by inhibiting the proinflammatory mediators. To validate our hypothesis, we used a well-characterized murine model of DED.
MATERIALS AND METHODS

Mouse Model of Dry Eye
Seven-to 8-week-old female C57BL/6 mice (Taconic Farms and Charles River Laboratories) were used in these experiments. DED was induced in the controlled environment chamber (CEC), and mice also received topical application of 1% atropine sulfate (Falcon Pharmaceuticals) twice daily for the first 48 hours and subcutaneous administration of scopolamine to maximize ocular dryness for 9 days as described previously. 7, 17 In brief, 0.5 mg/0.2 mL of scopolamine hydrobromide (Sigma-Aldrich) was injected subcutaneously in the dorsal skin of mice 3 times daily. The mice placed in the CEC were continuously exposed to a relative humidity of ,30%, a constant temperature of 21°C to 23°C, and an airflow of 15 L/min, 24 hours a day. Age-and sexmatched mice placed in the standard vivarium were used as normal controls. After 48 hours, induction of dry eye was confirmed by corneal fluorescein staining.
Corneal Fluorescein Staining
Corneal fluorescein staining was performed at baseline (day 0), 48 hours after the induction of dry eye (before topical administration), day 4, and day 9. One microliter of 1% fluorescein (Sigma-Aldrich) was applied to the inferolateral conjunctival sac of the mice, and after 3 minutes, corneal fluorescein staining was examined with a slit-lamp biomicroscope. Punctate staining was evaluated in a masked fashion using the National Eye Institute grading system, giving a score from 0 to 3 for each of the 5 areas of the cornea. 18 
Topical EGCG Formulations and Treatment Regimen
Topical EGCG (Sigma-Aldrich) was diluted with 1% dimethyl sulfoxide in phosphate-buffered saline (PBS). One percent dimethyl sulfoxide in PBS was used as the vehicle control. Both concentrations of 0.1% and 0.01% EGCG were used. Forty-eight hours after the induction of dry eye, the mice in the CEC were randomly divided into the following 4 groups (n = 3 in each group): an untreated group, a group receiving topical vehicle control, and each of 2 groups receiving topical 0.1% or 0.01% EGCG. Two microliters of the topical agent was applied to both eyes of each mouse twice a day (9 AM and 5 PM) from day 3 to day 9. Mice were then euthanized on day 9 for cellular and molecular studies.
RNA Isolation and Real-Time Polymerase Chain Reaction
Total RNA was isolated from the dissected corneal tissue using TRIzol (Invitrogen) and the RNeasy MicroKit (Qiagen). The first strand of complementary DNA was synthesized with random hexamers using SuperScript III reverse transcriptase (Invitrogen), and quantitative real-time polymerase chain reaction (PCR) was performed using Taqman Universal PCR Mastermix and FAM-MGB dye-labeled predesigned primers (Applied Biosystems) for IL-1b (Mm00434228_m1), TNF-a (Mm99999068_m1), CCL2 (Mm00439620_m1), vascular endothelial growth factor (VEGF)-A (Mm00437304_ml), VEGF-C (Mm00437313_ml), VEGF-D (Mm00438965_ml), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Mm99999915_g1). One microliter of complementary DNA was loaded in each well, and the assays were performed in duplicate. The GAPDH gene was used as the endogenous reference for each reaction. The results were analyzed by the comparative threshold cycle method, and the relative expression level of each sample was expressed as fold change from normal control.
Analysis of Cellular Infiltration by Immunohistochemical Staining
The following primary antibodies were used for immunohistochemical staining: fluorescein isothiocyanate (FITC)-conjugated rat anti-mouse CD11b (1:100, monocyte/-macrophage marker; BD Pharmingen, San Diego, CA) and FITC-conjugated rat immunoglobulin G2bk (isotype control; BD Pharmingen). For whole-mount corneal staining for CD11b cells, excised corneas were fixed in acetone for 15 minutes at day 9. The immunostaining was performed as described previously. 7, 19 Nonspecific staining was blocked with anti-FcR CD16/CD32 antibody (BD Pharmingen), and the specimens were immunostained with primary or isotype antibodies overnight, washed with PBS, incubated with secondary antibodies, and mounted using Vector Shield mounting medium with 4#,6-diamidino-2-phenylindole (DAPI; Vector Laboratories).
Three corneas from 3 mice per group were taken, and CD11b+ cells were counted in 4 to 6 areas in the periphery (0.5-mm area from the limbus) and 2 areas in the center (central 2-mm area) of each cornea in a masked fashion by using an epifluorescence microscope (model E800; Nikon) at 340 magnification. The mean number of cells was obtained by averaging the cell number in each area examined.
Analysis of Corneal Lymphangiogenesis by Immunohistochemical Staining
The following primary antibodies were used for immunohistochemical staining: FITC-conjugated rat antimouse CD31/PECAM-1 (1:100; Santa Cruz Biotechnology, Santa Cruz, CA), goat anti-rabbit lymphatic vessel endothelial hyaluronan receptor (LYVE)-1 antibody (1:200; Abcam), and rhodamine-conjugated secondary antibody (1:100; Santa Cruz Biotechnology). For whole-mount corneal staining for CD31/LYVE-1 cells, freshly excised corneas were fixed in acetone for 15 minutes at day 9. The specimens were stained with primary antibodies overnight, incubated with secondary antibodies, and mounted using Vector Shield mounting medium with DAPI. To quantify corneal lymphangiogenesis, pictures of whole corneal flat mounts were taken under an epifluorescence microscope at 320 magnification. The lymphatic areas covered by CD31 low LYVE-1 high vessels were analyzed using Matlab (The MathWorks, Inc, Natick, MA) and expressed as a percentage of the whole corneal area outlined using the innermost vessel of the limbal arcade as the border. 20 
TUNEL Assay
As an alternative to clinical assessment, we evaluated surface epitheliopathy by means of the terminal transferase dUTP nick end labeling (TUNEL) assay. To evaluate corneal epitheliopathy, 7-mm cryostat cross-sections were fixed in 4% paraformaldehyde in PBS at day 9, and TUNEL staining was performed according to the manufacturer's protocol (TUNEL Kit; Roche). One cryosection was incubated with 1 mm/mL of DNase I for 10 minutes at room temperature before labeling procedures as a positive control, and 1 cryosection was incubated without terminal transferase as a negative control. Each section was counterstained with Vectashield mounting medium with DAPI. Images were obtained at the central cornea under an epifluorescence microscope with 340 magnification. TUNEL-positive and DAPI-negative areas were excluded as artifacts. Both TUNEL-positive cells and DAPI-positive cells were counted in the 100-mm-wide 3 40-mm-deep areas of the central cornea epithelial layer in a masked fashion as in previous studies.
21,22
Statistical Analyses
Data are expressed as means 6 standard errors of the mean of 3 independently repeated experiments. Statistical significance among the groups was analyzed by the 2-tailed t test using Prism software (version 5.0; GraphPad, San Diego, CA). P , 0.05 was considered statistically significant.
RESULTS
Effect of Topical EGCG on Clinical Signs of DED
Mice were placed in the CEC at day 0. Two days after dry eye induction, mice were randomized into 4 groups: (1) group 1, topical application of 0.01% EGCG; (2) group 2, 0.1% EGCG; (3) group 3, vehicle; and (4) group 4, no eye drops (untreated controls). At day 4, all treatment groups, including vehicle, showed a significant decrease in corneal staining compared with the untreated group, but there was no difference in staining among these treatment groups. However, by day 9, 0.1% EGCG-treated eyes showed significantly decreased corneal staining compared with the untreated group (41.9% of decrease, P , 0.001) and vehicle-treated group (24.6%, P = 0.001). No significant difference was noted between the 0.01% EGCG-treated and vehicle-treated groups (P = 0.356; Fig. 1 ).
Effect of Topical EGCG on Corneal Infiltration of Inflammatory Cells
The number of central corneal CD11b+ cells in the EGCG treatment groups was found to be significantly decreased compared with the untreated group (36.2% of decrease for 0.1% EGCG, P , 0.001; 33.1% of decrease for 0.01% EGCG, P = 0.001) and the vehicle-treated group (26.1% for 0.1% EGCG, P = 0.009; 22.6% for 0.01% EGCG, P = 0.025) (Figs. 2A, B) . In the corneal periphery, 0.1% EGCG treatment also showed a significant decrease in the number of CD11b+ cells compared with the untreated group (39.9%, P , 0.001) and the vehicle-treated group (23.3%, P = 0.001), whereas 0.01% EGCG treatment led only to a decrease in CD11b+ cells compared with the untreated group (25.3%, P, 0.001), but not with the vehicle-treated group (P = 0.517).
Effect of EGCG on Inflammatory Cytokine Expression in the Corneas
Real-time PCR was used to quantify the transcripts encoding IL-1b, TNF-a, and CCL2 in the corneas of the different groups (Fig. 3) . Treatment with topical 0.1% EGCG significantly decreased the relative expression of IL-1b (P = 0.015 vs. untreated and P = 0.029 vs. vehicle) and CCL2 transcripts (P = 0.017 vs. untreated and P = 0.001 vs. vehicle). EGCG 0.01% decreased the relative expression of IL-1b (P = 0.024 vs. untreated) and CCL2 transcripts (P = 0.039 vs. untreated and P = 0.006 vs. vehicle, respectively). However, there was no association between TNF-a transcripts with any of the treatments.
Effect of EGCG on DED-Induced Corneal Lymphangiogenesis
Real-time PCR was used to quantify the transcripts encoding the proangiogenic and prolymphangiogenic growth factors (VEGF-A, VEGF-C, and VEGF-D) in the cornea of the different groups (Fig. 4) . At day 9, the relative expressions of all these VEGF species had increased in the untreated group to 2-to 5-fold compared with those seen in the normal control group. EGCG 0.1% treatment significantly decreased the relative expression of VEGF-A (P = 0.007 vs. untreated) and VEGF-D transcripts (P = 0.048 vs. untreated). 0.1% EGCG treatment showed considerable decrease in VEGF-C levels compared with the untreated controls, although this was not statistically significant (P = 0.129).
The area of corneal lymphangiogenesis was significantly increased in the dry eye state (2.4 times that of normal controls, P = 0.023). Although there was a very modest 
Effect of EGCG on Apoptosis of the Corneal Epithelial Cells
The numbers of apoptotic cells were significantly increased in dry eye corneas compared with normal controls (P , 0.0001). Both 0.01% and 0.1% EGCG treatments showed a significant decrease in the number of apoptotic epithelial cells compared with the untreated group (P = 0.009 and P = 0.003, respectively). The vehicle-treated group also showed a significant reduction in epithelial apoptosis compared with the untreated group; there was no significant difference between vehicle-and EGCG-treated groups in the level of apoptosis (Fig. 6) .
DISCUSSION
We present herein data demonstrating that topical 0.1% EGCG can decrease the clinical signs and inflammatory responses of the ocular surface in DED. The therapeutic and prophylactic uses of green tea have been confined to ''alternative medicine,'' but recent studies clearly suggest that EGCG, a major active component of the polyphenolic fraction of green tea, has anticarcinogenic, antiinflammatory, antioxidant, and antiangiogenic effects both in vitro and in vivo. 10, 11, [23] [24] [25] DED is a complex and multifactorial inflammatory condition. In our study, we have shown that some Real-time PCR analysis showing that 0.1% and 0.01% EGCG significantly decreased the relative expressions of (A) IL-1b (*P , 0.05) and (B) CCL2 (*P , 0.05; †P , 0.01) but not of (C) TNF-a transcripts in dry eye corneas. Data were normalized to GAPDH messenger RNA as internal control and then values were expressed as the fold change over the normal control corneas. Data are presented as mean 6 standard error of the mean of 3 experiments. Each experiment consisted of 2 to 3 corneas per group. inflammatory mediators, such as IL-1b (7.1 times), TNF-a (2.1 times), and CCL2 (2.9 times), are increased in dry eyeinduced cornea, compared with normal control. These mediators can induce immune-mediated inflammation, such as the activation of antigen-presenting cells (APCs), and aggravate ocular surface cell damage. 19, 26, 27 Previous studies have shown that the corneal infiltration by CD11b+ APCs is increased in dry eye, and IL-1b induces the loss of corneal epithelial barrier function associated with ocular inflammation in a nuclear factor-kB-dependent manner. 19, 26, 27 In this study, we demonstrated that topical 0.1% EGCG significantly reduces the ocular surface inflammation by decreasing the expression levels of IL-1b and CCL2. Moreover, our data showed that topical EGCG decreases the number of CD11b+ cells in dry eye corneas, which may be associated with the reduced expression of inflammatory mediators, such as IL-1b and CCL2. Although our data clearly demonstrate decreased numbers of CD11b+ cells in DED corneas with EGCG treatment, the mere presence or absence of these CD11b+ cells may not reflect their functional status. Therefore, further studies may be needed to confirm the effect of EGCG on CD11b+ activation and function. CCL2 is the important chemokine regulating the migration and infiltration of monocytes and macrophages that have a key role in initiating the inflammatory process in dry eye. 24, 28, 29 Previous studies have reported that EGCG treatment decreases the expression of CCL2, resulting in a decreased number of monocytes, and EGCG could induce T-cell tolerance during dendritic cell-T-cell interaction by inhibiting the maturation of dendritic cells. 12, 29 Our previous study has shown that corneal lymphangiogenesis, but not angiogenesis, is significantly induced in DED. 30 Thus, lymphatics could have a key role in the induction of autoimmunity in DED by providing peripheral APC access to the lymphoid compartment to activate T cells. In this study, we also found that the areas of corneal lymphatic growth and the expressions of VEGF-A, VEGF-C, and VEGF-D messenger RNAs are significantly increased in the dry eye model compared with normal controls. Previous studies reported that EGCG can reduce VEGF expression at the transcriptional level in cell culture and animal models, and that the antiangiogenic effect of green tea is important for cancer prevention considering its low side effects. 25, [31] [32] [33] In the current study, topical EGCG showed a significant decrease in the expression of prolymphangiogenic VEGF-D in dry eye corneas, but overall reduction in the corneal lymphatic growth was modest.
Yeh et al 21 demonstrated that proinflammatory cytokines, such as TNF-a and IL-1, can increase the apoptosis of ocular surface epithelial cells in dry eyes, and the punctate epithelial erosions that are observed in the cornea and conjunctiva of patients with DED could be attributed to sloughing of apoptotic epithelial cells. Similarly, in our study, we also found an increase in epithelial cell apoptosis in dry eye-induced corneas. Using the TUNEL assay, we evaluated the effect of EGCG on prevention of dry eye and/or druginduced epithelial cell apoptosis. Topical 0.01% and 0.1% EGCG showed no toxicity and significantly reduced the epithelial cell apoptosis. However, this decrease in apoptosis was not significantly different from vehicle-treated dry eyes. In conclusion, we have demonstrated that the topical application of EGCG in experimental dry eyes leads to significant improvement in clinical signs and inflammation-associated ocular surface pathologies. 
